(19)
(11) EP 2 694 972 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
16.08.2017 Bulletin 2017/33

(45) Mention of the grant of the patent:
21.06.2017 Bulletin 2017/25

(21) Application number: 12716858.1

(22) Date of filing: 04.04.2012
(51) International Patent Classification (IPC): 
G01N 33/574(2006.01)
(86) International application number:
PCT/US2012/032206
(87) International publication number:
WO 2012/138785 (11.10.2012 Gazette 2012/41)

(54)

METHODS FOR PREDICTING AND IMPROVING THE SURVIVAL OF GASTRIC CANCER PATIENTS

VERFAHREN ZUR VORHERSAGE UND VERBESSERUNG DER ÜBERLEBENSZEIT VON MAGENKREBSPATIENTEN

PROCÉDÉS POUR PRÉDIRE ET AMÉLIORER LA SURVIE DE PATIENTS ATTEINTS DE CANCER GASTRIQUE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 04.04.2011 US 201161471678 P
25.01.2012 US 201261590787 P

(43) Date of publication of application:
12.02.2014 Bulletin 2014/07

(73) Proprietor: Pierian Holdings, Inc.
Franklin, TN 37067 (US)

(72) Inventors:
  • KIM, Phillip
    Irvine, CA 92612 (US)
  • SINGH, Sharat
    Rancho Santa Fe, CA 92127 (US)

(74) Representative: J A Kemp 
14 South Square Gray's Inn
London WC1R 5JJ
London WC1R 5JJ (GB)


(56) References cited: : 
WO-A1-2011/008990
   
  • BACHLEITNER-HOFMANN T. ET AL.: "Stimulation of epidermal growth factor (EGFR) or HER-3 mediates resistance to MET tyrosine kinase inhibition in MET-amplified gastric cancer cells", PROC. AM. ASS. CANCER RES. ANN. MEETING, vol. 49, April 2008 (2008-04), page 1186, XP002678285, & 99TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; SAN DIEGO, CA, USA; APRIL 12 -16, 2008
  • BACHLEITNER-HOFMANN T. ET AL.: "Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET inhibition", CLIN. CANCER RES., vol. 17, no. 1, 1 January 2011 (2011-01-01), pages 122-133, XP55030286,
  • MUKOHARA T. ET AL.: "Foretinib (GSK1363089) inhibits growth of gastric cancer cell lines through blockade of inter-receptor tyrosine kinases networks", EUR. J. CANCER, vol. 8, no. 7, #109, November 2010 (2010-11), page 42, XP027497797,
  • TABERNERO J. ET AL.: "Integration of targeted therapies", EUR. J. CANCER, vol. 7, no. 2, #305, September 2009 (2009-09), page 74, XP026689064,
  • BACHLEITNER-HOFMANN T. ET AL.: "HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells", MOL. CANCER THER., vol. 7, no. 11, November 2008 (2008-11), pages 3499-3508, XP55020686,
  • CORSO S. ET AL.: "Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition", MOL. CANCER, vol. 9, no. 1, 26 May 2010 (2010-05-26), page 121, XP021077869,
  • PENTHEROUDAKIS G. ET AL.: "Incorporation of Targeted Agents in the Management of Patients with Advanced Gastric Cancer", CURR. MED. CHEM., vol. 18, no. 11, 1 April 2011 (2011-04-01) , pages 1629-1639, XP002678286,
  • KIM P. ET AL.: "Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients", PROTEOME SCIENCE, vol. 9, no. 1, 15 December 2011 (2011-12-15), page 75, XP55030160,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).